Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
評估 Felzartamab 在抗磷脂酶 A2 受體自體抗體陽性原發性膜性腎病中的安全性和有效性的 1b/2a 階段研究。
Kidney Int Rep 2024-09-18
Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations.
心血管-腎臟-代謝綜合症中心血管、腎臟及代謝疾病的結合,及新的風險預測方程式。
Kidney Int Rep 2024-09-18
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理:使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是其他相關的問題,請提供更多細節!
相關文章PubMedDOI
Immunoadsorption and Plasma Exchange are Comparable in Anti-Neutrophil Cytoplasmic Antibodies or Anti-Glomerular Basement Membrane Removal Kinetics.
免疫吸附與血漿交換在抗中性粒細胞胞漿抗體或抗腎小球基底膜去除動力學上具有可比性。
Kidney Int Rep 2024-09-18
Pericatheter Leak Associated With Earlier Peritoneal Dialysis Initiation Does Not Influence Long-Term Outcomes.
早期開始腹膜透析相關的導管周圍漏液不影響長期結果。
Kidney Int Rep 2024-09-18
Gene Expression Sets and Renal Profiling from the Renal AL Amyloid Involvement and NEOD00 (RAIN) Trial.
來自腎臟 AL 淋巴瘤參與及 NEOD00 (RAIN) 試驗的基因表達集和腎臟剖析。
Kidney Int Rep 2024-09-18
Validation of a Clinical Scale for Early Detection of Infections at the Exit Site of Central Venous Catheters for Hemodialysis.
中央靜脈導管出口部位感染早期檢測臨床量表的驗證。
Kidney Int Rep 2024-09-18